AUSTIN, Texas— Gameto, a clinical-stage biotech company, has announced promising results for its novel fertility treatment Fertilo, achieving more than double the pregnancy rate of traditional in vitro maturation (IVM) methods.
In a 40-patient study, women who underwent a mini stimulation (mini stim) cycle with Fertilo—an investigational product made from lab-grown ovarian support cells (OSCs) derived from human-induced pluripotent stem cells (iPSCs)—achieved a 44% pregnancy rate per cycle after the first embryo transfer. That’s more than twice the 20% success rate seen with standard IVM.
The study also showed significant improvements in egg maturation and embryo quality. Eggs matured with Fertilo had a 70% maturation rate compared to 52% with standard IVM. Additionally, the rate of creating healthy, chromosomally normal embryos (euploid blastocysts) was five times higher using Fertilo.
Eight out of ten patients in the Fertilo group had at least one viable embryo for implantation, compared to just three out of ten in the control group.
“Fertilo represents a faster, safer, and more patient-centered approach to family building,” said Gameto CEO Dr. Dina Radenkovic. “It’s designed for all individuals looking to conceive, and it reduces the physical and emotional strain often associated with IVF.”
Dr. Christian Kramme, Chief Scientific Officer at Gameto, added, “These results highlight the transformative potential of iPSC-derived therapies in reproductive medicine.”
Gameto plans to expand access to Fertilo through an upcoming U.S. pivotal study and global trials.
